Table 2.

Multivariate analysis of factors affecting intracranial PFS and OS in the patients

Factors	Intracranial PFS				OS
	HR		95% CI	p	HR	95% CI	p
All patients
Gender	0.393	0.141–1.101		0.076	0.242	0.085–0.692	0.008
Age	1.190	0.545–2.601		0.663	1.260	0.593–2.678	0.548
KPS	1.065	0.979–3.357		0.057	1.950	0.370–5.349	0.006
Lung-molGPA	0.721	0.496–1.048		0.086	0.665	0.452–0.978	0.038
Smoking	0.430	0.180–1.026		0.057	0.297	0.121–0.728	0.008
Histology	0.875	0.457–1.674		0.686	0.637	0.337–1.205	0.166
RT group
Gender	0.824	0.221–3.071		0.773	0.464	0.100–2.161	0.328
Age	1.751	0.576–5.317		0.323	1.748	0.529–5.774	0.360
KPS	1.232	0.707–6.050		0.171	1.178	0.901–7.202	0.072
Lung-molGPA	0.664	0.376–1.170		0.156	0.623	0.345–1.125	0.117
Smoking	0.261	0.063–1.085		0.065	0.242	0.054–1.088	0.064
Histology	0.502	0.183–1.375		0.180	0.675	0.229–1.992	0.476
Apatinib+RT group
Gender	0.050	0.005–0.519		0.012	0.083	0.014–0.494	0.006
Age	0.895	0.310–2.586		0.838	1.185	0.442–3.176	0.736
KPS	1.587	0.708–3.555		0.262	1.300	0.941–4.622	0.068
Lung-molGPA	0.737	0.437–1.243		0.252	0.691	0.411–1.162	0.163
Smoking	0.463	0.139–1.536		0.208	0.277	0.089–0.862	0.027
Histology	0.874	0.335–2.281		0.784	0.774	0.321–1.867	0.569

progression-free survival: PFS; overall survival: OS; hazard ratio: HR; confidence interval: CI; Karnofsky Performance Status: KPS.